SPDL1 and acute respiratory distress syndrome: In this regard, as a result of sPD-L1 administration, inflammatory lung injury was effectively relieved, and the survival rate was improved in mice with direct ARDS, suggesting sPD-L1 as a promising agent in the recovery of COVID-19 patients with direct ARDS [25].